Grades and Levels of Evidence: Difference between revisions

No edit summary
No edit summary
Line 37: Line 37:
| All or none series<br>  
| All or none series<br>  
| All or none case serires<br>  
| All or none case serires<br>  
| Absoulute [[Test_Diagnostics|SpPins and SnNouts]]<br>  
| Absoulute [[Test Diagnostics|SpPins and SnNouts]]<br>  
| All or none case series<br>  
| All or none case series<br>  
| Absolute better-value or worse-value analyses<br>
| Absolute better-value or worse-value analyses<br>
Line 48: Line 48:
| SR (with homogeneity) of Level &gt;2 economic studies<br>
| SR (with homogeneity) of Level &gt;2 economic studies<br>
|-
|-
| 2B<br>  
| '''2B'''<br>  
| <br>  
| Individual cohort study (including low quality RCT; e.g., &lt;80% follow-up)<br>  
| <br>  
| Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR or validated on split-sample only<br>  
| <br>  
| Exploratory cohort study with good reference standards; CDR after derivation, or validated only on split-sample or databases<br>  
| <br>  
| Retrospective cohort study, or poor follow-up<br>  
| <br>
| Analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies; and including multi-way sensitivity analyses<br>
|-
|-
| 2C<br>  
| 2C<br>  

Revision as of 16:36, 8 June 2009

Original Editor - Tyler Shultz

Lead Editors - Your name will be added here if you are a lead editor on this page.  Read more.

Discussion & Background[edit | edit source]

Levels of Evidence[edit | edit source]


Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998.
Level
Therapy/Prevetion, Aetiology/Harm
Prognosis
Diagnosis
Differential Diagnosis
Economic and Descision Analysis
1A
SR (with homogeneity) of RCTs
SR (with homogeneity) of inception cohort studies; CDR validated in different populations
SR (with homogeneity) of Level 1 diagnostic studies; CDR with 1b studies from different clinical centres
SR (with homogeneity) of prospective cohort studies
SR (with homogeneity) of Level 1 economic studies
1B
Individual RCT (with narrow Confidence Interval)

Individual inception cohort study with > 80% follow-up; CDR validated in a single population
Validating cohort study with good reference standards; or CDR tested within one clinical centre

Prospective cohort study with good follow-up
Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses
1C
All or none series
All or none case serires
Absoulute SpPins and SnNouts
All or none case series
Absolute better-value or worse-value analyses
2A
SR (with homogeneity) of cohort studies

SR (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs
SR (with homogeneity) of Level >2 diagnostic studies
SR (with homogeneity) of 2b and better studies
SR (with homogeneity) of Level >2 economic studies
2B
Individual cohort study (including low quality RCT; e.g., <80% follow-up)
Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR or validated on split-sample only
Exploratory cohort study with good reference standards; CDR after derivation, or validated only on split-sample or databases
Retrospective cohort study, or poor follow-up
Analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies; and including multi-way sensitivity analyses
2C





3A





3B





4





5





Grades of Evidence[edit | edit source]

Recent Related Research (from Pubmed)[edit | edit source]

Extension:RSS -- Error: Not a valid URL: Feed goes here!!|charset=UTF-8|short|max=10

References[edit | edit source]